Showing 5241-5250 of 8820 results for "".
- Galderma Forms Women In Aesthetics Leadership Councilhttps://practicaldermatology.com/news/galderma-forms-women-in-aesthetics-council/2459928/Galderma Laboratories, L.P. has formed a Women in Aesthetics Leadership Council, comprised of clinicians, clinical trial investigators, CEOs, business owners, and practice managers. "In most industries in the US women hold just 25 percent of senior leadership positions
- Alan Menter, MD Receives Outstanding Researcher and Educator in Psoriatic Disease Award from ODAC, JDDhttps://practicaldermatology.com/news/alan-menter-md-receives-outstanding-researcher-and-educator-in-psoriatic-disease-award-from-odacjdd/2459929/Alan Menter, MD, has been awarded the Outstanding Researcher and Educator in Psoriatic Disease Award by the ODAC Dermatology, Aesthetics & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD). The award recognizes Dr. Menter’
- Gryphon Acquires Roc Skincare from J & Jhttps://practicaldermatology.com/news/gryphon-acquires-roc-skincare-from-j-j/2459930/Gryphon Investors has acquired RoC Skincare from Johnson & Johnson Consumer, Inc. The transaction is Gryphon's second investment in the beauty sector after the firm acquired indie color cosmet
- HydraFacial Company Partners With Alastin Skincarehttps://practicaldermatology.com/news/hydrafacial-company-partners-with-alastin-skincare/2459931/Alastin Skincare’s TriHex-Pro Skin Booster Serum is now available at HydraFacial providers across the United States. The key ingredient in the TriHex-Pro Skin Booster Serum is Alastin's proprieta
- Almirall's Seysara Now Availablehttps://practicaldermatology.com/news/seysara-now-available/2459932/SeysaraTM (sarecycline), a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne, is now commercially available from Almirall. Seysara™ was approved in October by FDA for the treatment of moderate to severe non-nodular inflammatory acne
- RealSelf Survey: 36 Percent of US Adults Are Considering Cosmetic Treatmentshttps://practicaldermatology.com/news/realself-36-percent-of-us-adults-are-considering-cosmetic-treatments/2459933/More than four in five U.S. adults want to improve their personal well-being or appearance in 2019, and 36 percent are considering cosmetic treatments, according to new RealSelf survey. Fully 82 percent of U.S. adults plan to make changes related to their personal well-being and/or appear
- Dermatologists Prescribe the Most Antibiotics, But Usage Is Changinghttps://practicaldermatology.com/news/dermatologists-prescribe-the-most-antibiotics-but-usage-is-changing/2459935/The use of antibiotics to treat inflammatory skin conditions like acne and rosacea is decreasing over time, but there has been an increase in prescriptions associated with dermatologic surgical procedures, a new study finds. The study appears in
- New Review Highlights Comprehensive Treatment Guidelines for Severe ADhttps://practicaldermatology.com/news/new-review-highlights-comprehensive-treatment-guidelines-for-severe-ad/2459936/A team of investigators from the University of Colorado College of Nursing at CU Anschutz Medical Campus and National Jewish Health has identified comprehensive guidelines for managing severe atopic dermatitis (AD). The
- Real Housewife Gets Real About Self-Care, Coolsculptinghttps://practicaldermatology.com/news/real-housewife-gets-real-about-self-care-coolsculpting/2459938/Bravo's "The Real Housewives of New York City” Sonja Morgan is the face of Coolscuplting’s new "Let's Get Real About Self-Care" campaign. Morgan joins CoolSculpting in its mission to encourage women across the country by moving self-care to the top of th
- LEO Pharma Focuses on Translational Medicine, Appoints Dr. Adam B. Raff as Director & Medical Advisorhttps://practicaldermatology.com/news/leo-pharma-strengthens-focus-on-translational-medicine-with-appointment-of-dr-adam-b-raff-as-director-medical-advisor/2459942/LEO Pharma has appointed Adam B. Raff, MD, PhD as Director and Medical Advisor in Translational Medicine, effective January 28. Dr. Raff’s primary objective will be to support LEO Pharma’s ambitions to advance science within dermatology through translational medicine, the company says